Less than one in 10 patients who could benefit from GLP-1 drugs like Wegovy can access them, warns the World Health Organization as it issues its first guidance on the medications.
Considering in excess of 1,000,000,000 individuals worldwide now classified as obese, it is urging increased and just access to this class of drugs.
According to estimates, in excess of 2,000,000,000 will be living with obesity by 2030 without intervention.
"Our new guidance recognises that excess weight is a long-term condition that can be treated with comprehensive and ongoing support," stated its chief Tedros Adhanom Ghebreyesus.
Substantial prices, limited production capacity, and distribution challenges are significant hurdles to widespread availability to the jabs that can assist patients in reducing significant weight, notes the agency.
Skinny Jab Supply Crisis
Despite the current best projected case, the manufacturing of such drugs might only reach about 100 million people – fewer than 10% of the global need, according to the health organization.
The advice calls on nations and manufacturers to widen access, through approaches such as voluntary licensing.
Exclusive production rights on a key compound – the main ingredient of the drug Wegovy – is due to expire in several countries in 2026.
How Weight-Loss Injections Function
These medications imitate a biological compound to delay gastric emptying, reduce hunger and increase satiety so users consume fewer calories.
Individuals usually begin shedding pounds in the initial weeks of commencing the regular doses.
Studies points to patients may put most of the weight back on a year later of halting the treatment, when their typical food cravings return.
Being above a healthy weight increases your risk for experiencing health problems, like type 2 diabetes, heart disease, brain attack, and specific malignancies.
Obesity impacts people in all nations and was associated with 3.7 million deaths worldwide in 2024, as per the health agency.
